RECORD // Company

Oruka Therapeutics, Inc.

Formerly: ARCA biopharma, Inc.; NUVELO INC; HYSEQ INC

Built 2026-11-22T00:41:33Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (2 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

Gleif lei (1)
SEC EDGAR (1)
Records under a former name (2)

The name on these records was this company's name in the past (SEC name history). An old name can also belong to an unrelated organization, so they are shown apart and are not counted above.

Matched by name only, not merged (1)

These records carry the same exact name as this company, but a name alone is not proof, so Seraphix holds them apart until name matching is verified (score due 11-21).

  • Oruka Therapeutics, Inc. · Ctgov · same registered legal name as 'Oruka Therapeutics, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare

2 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-09 · accession 0001213900-26-117518

ItemValuePeriodFormFiledAccessionReport
Net income (loss)$-49,965,0003 months ended 2026-09-3010-Q2026-11-090001213900-26-1175182026-11-22 00:41 UTCReport an error
Cash and cash equivalents$191,519,000at 2026-09-3010-Q2026-11-090001213900-26-1175182026-11-22 00:41 UTCReport an error

Negative as reported in the filing.

Not in this report's XBRL: Revenue, Interest expense.

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0000907654
Ticker
ORKA
EIN
363855489
CUSIP
687604108
Record ID
sx:sec:0000907654

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

32 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-20SEC EDGAR company profile2026-11-22 00:41 UTCReport an error
SIC industry2834 Pharmaceutical Preparations2026-11-20SEC EDGAR company profile2026-11-22 00:41 UTCReport an error
State of incorporationDE2026-11-20SEC EDGAR company profile2026-11-22 00:41 UTCReport an error
Fiscal year end (MMDD)12312026-11-20SEC EDGAR company profile2026-11-22 00:41 UTCReport an error
Business address855 OAK GROVE AVE., SUITE 100, MENLO PARK, CA, 940252026-11-20SEC EDGAR company profile2026-11-22 00:41 UTCReport an error
ExchangesNasdaq2026-11-20SEC EDGAR company profile2026-11-22 00:41 UTCReport an error
Net income (loss) (fiscal year ended 2025-12-31)$-105,433,0002025-12-3110-K, XBRL NetIncomeLoss2026-11-22 00:41 UTCReport an error
Total assets (at 2025-12-31)$488,617,0002025-12-3110-K, XBRL Assets2026-11-22 00:41 UTCReport an error
Stockholders' equity (at 2025-12-31)$471,930,0002025-12-3110-K, XBRL StockholdersEquity2026-11-22 00:41 UTCReport an error
Cash and cash equivalents (at 2025-12-31)$46,935,0002025-12-3110-K, XBRL CashAndCashEquivalentsAtCarryingValue2026-11-22 00:41 UTCReport an error
Operating cash flow (fiscal year ended 2025-12-31)$-88,210,0002025-12-3110-K, XBRL NetCashProvidedByUsedInOperatingActivities2026-11-22 00:41 UTCReport an error
Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31)$209,0002025-12-3110-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment2026-11-22 00:41 UTCReport an error
Operating lease liabilities (at 2025-12-31)$1,932,0002025-12-3110-K, XBRL OperatingLeaseLiability2026-11-22 00:41 UTCReport an error
Form D total offering amount (D filed 2015-06-25)$51,650,4042015-06-25D2026-11-22 00:41 UTCReport an error
Form D total amount sold (D filed 2015-06-25)$51,650,4042015-06-25D2026-11-22 00:41 UTCReport an error
Form D industry groupPharmaceuticals2015-06-25D2026-11-22 00:41 UTCReport an error
Form D revenue rangeDecline to Disclose2015-06-25D2026-11-22 00:41 UTCReport an error
Form D date of first sale2015-06-162015-06-25D2026-11-22 00:41 UTCReport an error
8-K Item 7.01, Regulation FD Disclosure (filed 2026-10-26)On October 26, 2026, Oruka Therapeutics, Inc. (“Oruka” or the “Company”) issued a press release and made publicly available a data presentation announcing Week 16 results from its Phase 2b EVERLAST-B clinical trial of ORKA-001, an investigational, half-life extended IL-23p19 monoclonal antibody, in patients with moderate-to-severe plaque psoriasis (“PsO”). Oruka will host a conference call and webcast today, Monday, October 26, 2026, at 8:00 a.m. Eastern Time, to discuss the results. The information in this Item 7.01 of this Current Report on Form 8-K, including the information in the press release and presentation attached as Exhibits 99.1 and 99.2 to this Current Report on Form 8-K, is…2026-10-26SEC EDGAR 8-K 0001213900-26-112281 (text as filed, excerpt)2026-11-22 00:41 UTCReport an error
8-K Item 8.01, Other Events (filed 2026-10-26)On October 26, 2026, Oruka announced Week 16 results from its Phase 2b EVERLAST-B clinical trial of ORKA-001 in patients with moderate-to-severe PsO. EVERLAST-B Phase 2b Key 16-Week Results EVERLAST-B is a randomized, double-blind, placebo-controlled Phase 2b clinical trial evaluating the safety, efficacy and pharmacokinetics of ORKA-001 in patients with moderate-to-severe PsO. The trial enrolled 187 patients randomized 1:1:1:1 to receive 37.5 mg of ORKA-001 at Week 0 (“Low Dose”), 300 mg at Weeks 0 and 4 (“Mid Dose”), 600 mg at Weeks 0 and 4 (“High Dose”), or placebo. The primary endpoint is the proportion of patients achieving PASI 100 at Week 16. At Week 28, patients who achieve PASI 100…2026-10-26SEC EDGAR 8-K 0001213900-26-112281 (text as filed, excerpt)2026-11-22 00:41 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-08-10)On August 10, 2026, Oruka Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this report. The information in this Item 2.02, including Exhibit 99.1 to this report, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Exchange Act or under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in…2026-08-10SEC EDGAR 8-K 0001213900-26-086933 (text as filed, excerpt)2026-11-22 00:41 UTCReport an error
Plan (pension, plan no. 004)ORUKA THERAPEUTICS 401(K) PLAN: 69 participants2025-12-31DOL EBSA Form 5500 public datasets (dataset)2026-11-22 00:41 UTCReport an error
Largest institutional holder #1 (13F as filed): FMR LLC$862,016,0752026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:41 UTCReport an error
Largest institutional holder #2 (13F as filed): BlackRock, Inc.$474,915,5262026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:41 UTCReport an error
Largest institutional holder #3 (13F as filed): Venrock Adviser, LLC$394,805,8932026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:41 UTCReport an error
Largest institutional holder #4 (13F as filed): Fairmount Funds Management LLC$352,629,7852026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:41 UTCReport an error
Largest institutional holder #5 (13F as filed): Capital World Investors$323,733,9842026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:41 UTCReport an error
Largest institutional holder #6 (13F as filed): RTW INVESTMENTS, LP$298,741,4852026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:41 UTCReport an error
Largest institutional holder #7 (13F as filed): STATE STREET CORP$254,384,1172026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:41 UTCReport an error
Largest institutional holder #8 (13F as filed): VANGUARD CAPITAL MANAGEMENT LLC$224,693,6102026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:41 UTCReport an error
Largest institutional holder #9 (13F as filed): Paradigm Biocapital Advisors LP$204,094,5392026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:41 UTCReport an error
Largest institutional holder #10 (13F as filed): Deep Track Capital, LP$183,297,4202026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:41 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.